» Articles » PMID: 34644422

Association of Human Leukocyte Antigen Mismatches Between Donor-recipient and Donor-donor in Pancreas After Kidney Transplant Recipients

Overview
Journal Transpl Int
Specialty General Surgery
Date 2021 Oct 13
PMID 34644422
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of HLA mismatching on pancreas outcomes among pancreas after kidney (PAK) recipients are undefined. Outcomes might potentially differ depending on whether there is a mismatch between pancreas donor and recipient (PD-R) or pancreas donor and kidney donor(PD-KD). All primary PAK at our centre were included in this study. Patients were divided into two groups based on the degree of HLA mismatching: low (L-MM) as 0-4 and high (H-MM) as 5-6. We analysed all (N = 73) PAK for PD-R mismatch and the subset of PAK for PD-KD mismatch (N = 71). Comparing PD-R L-MM (n = 39) and H-MM (n = 34) PAKs, we observed no difference in the rate of pancreas graft failure. There was also no difference in the rate of rejection (L-MM 33% vs. H-MM 41%) or the severity of rejection. However, we observed a significantly (P < 0.01) shorter time to acute pancreas rejection in the H-MM group (6.8 ± 8.7 mo) versus the L-MM cohort (29.0 ± 36.2 mo) (P < 0.001). Similar to the PD-R mismatched cohort, we did not observe a detrimental effect of HLA mismatching on graft outcomes in the PD-KD cohort; time to rejection was again shorter in the H-MM subset. In this study, we found no impact of HLA mismatch on either pancreas graft survival or rejection rates, though rejection occurred earlier in high mismatched PAK transplants.

Citing Articles

Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge.

Caldara R, Tomajer V, Monti P, Sordi V, Citro A, Chimienti R Front Immunol. 2023; 14:1323439.

PMID: 38077372 PMC: 10701551. DOI: 10.3389/fimmu.2023.1323439.


Matching for HLA-DR excluding diabetogenic HLA-DR3 and HLA-DR4 predicts insulin independence after pancreatic islet transplantation.

Ballou C, Barton F, Payne E, Berney T, Villard J, Meier R Front Immunol. 2023; 14:1110544.

PMID: 37026004 PMC: 10070978. DOI: 10.3389/fimmu.2023.1110544.